secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001493152-25-017328
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity reports Q3 CyPath® Lung test sales up 95% QoQ, 97% YTD
------------------------------------------------------------------

- CyPath® Lung test sales in Q3 2025 increased 95% over Q2 2025; nine-month sales up 97% vs same period 2024.
- Growth driven by adoption at Veterans’ hospitals and market expansion in the mid-Atlantic region.
- New patients using CyPath® Lung rose 77% in Q3; patient compliance for at-home sample collection improved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225017328/0001493152-25-017328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225017328/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer